Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Autor: Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH

Publikováno v: Annals of Hematology; Aug2012, Vol. 91 Issue 8, p1161-1174, 14p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.

Autor: Mitzlaff K; Department of Medicine I, University Medical Center-Campus Lübeck, Lübeck, Germany., Kirstein MM; Department of Medicine I, University Medical Center-Campus Lübeck, Lübeck, Germany., Müller C; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Hospital, Magdeburg, Germany., Venerito M; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Hospital, Magdeburg, Germany., Olkus A; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany., Dill MT; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany., Weinmann A; Department of Internal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Kocheise L; I. Department for Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Busch A; Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schulze K; I. Department for Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Allo G; Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Waldschmidt DT; Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Barsch M; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Disease, University Medical Center, Freiburg, Germany., Bengsch B; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Disease, University Medical Center, Freiburg, Germany., Quante M; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Disease, University Medical Center, Freiburg, Germany., Gonzalez-Carmona MA; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Himmelsbach V; Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany., Finkelmeier F; Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany., Kloeckner R; Department for Interventional Radiology, University Medical Center-Campus Lübeck, Lübeck, Germany., Schirmacher P; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Marquardt JU; Department of Medicine I, University Medical Center-Campus Lübeck, Lübeck, Germany., Zimpel C; Department of Medicine I, University Medical Center-Campus Lübeck, Lübeck, Germany.

Publikováno v: United European gastroenterology journal [United European Gastroenterol J] 2024 Nov; Vol. 12 (9), pp. 1230-1242. Date of Electronic Publication: 2024 Sep 20.

Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.

Autor: Zhang D; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany., Benedikt Westphalen C; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany., Quante M; Medizinische Klinik II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany and Innere Medizin II, Universitätsklinik Freiburg, Universität Freiburg, Germany., Waldschmidt DT; Clinic for Gastroenterology and Hepatology, University Hospital Cologne, Germany., Held S; ClinAssess GmbH, Leverkusen, Germany., Kütting F; Clinic for Gastroenterology and Hepatology, University Hospital Cologne, Germany., Dorman K; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany., Heinrich K; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany., Weiss L; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany., Boukovala M; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany., Haas M; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany; Department of Hematology and Oncology, München Klinik Neuperlach, Munich, Germany., Boeck S; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany; Department of Hematology and Oncology, München Klinik Neuperlach, Munich, Germany., Heinemann V; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany; German Cancer Consortium (DKTK partner site Munich), Heidelberg, Germany. Electronic address: Volker.Heineman@med.uni-muenchen.de., Probst V; Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany. Electronic address: victoria.probst@med.uni-muenchen.de.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Apr; Vol. 201, pp. 113926. Date of Electronic Publication: 2024 Feb 15.

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

Autor: Reutter T; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Fassunke J; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Püsken M; Faculty of Medicine and University Hospital Cologne, Institute for Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany., Weber JP; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Binot E; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Eisert A; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Fischer R; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Nogova L; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Riedel R; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Schaufler D; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Scharpenseel H; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Scheffler M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Schulz H; Practice for Clinical Hematology and Oncology, Frechen, Germany., Waldschmidt DT; Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Zander T; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Merkelbach-Bruse S; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Schirmacher P; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Büttner R; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Wolf J; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany., Michels S; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2023 Apr; Vol. 7, pp. e2200467.